Advanced hepatocellular carcinoma (aHCC) has a dire prognostic outlook, with an 18.4% five-year survival rate in non-metastatic and a 2% survival in metastatic disease. At the European Society of Medical Oncology (ESMO) Congress 2024, the results of the Phase III APOLLO trial, assessing the viability of an immunotherapy-tyrosine kinase inhibitor (IO-TKI) combination for treating aHCC in the first line were presented.
The study evaluated Chia Tai Tianqing Pharmaceutical’s Focus V (anlotinib) in combination with Akeso’s penpulimab. Focus V is a novel multi-kinase inhibitor that acts on vascular endothelial, fibroblast, and platelet-derived growth factor receptors effectively fulfilling a potent multirole in tumor angiogenesis, and penpulimab is a programmed cell death protein 1 (PD-1) checkpoint inhibitor. The study randomised 649 patients 2:1 to the Focus V plus penpulimab combination (n=423) or the long-established sorafenib (n=212). The progression-free survival (PFS) showed significant benefit with the Focus V arm, with a median PFS of 6.9 months compared to sorafenib’s 2.8 months (p<0.0001). Overall survival (OS) improved similarly to PFS in the Focus V treatment arm (16.5 vs 13.2 months; p=0.0012). The safety profile of the Focus V arm was manageable, with fewer treatment-related adverse events (TRAEs) compared to sorafenib.
Go deeper with GlobalData
This news was well received at ESMO owing to the previous failure of the LEAP-002 trial, where Merck & Co’s Keytruda (pembrolizumab) could not prove clinically significant benefit in combination with levantinib.
Elevar Therapeutics’ PD-1 IO camrelizumab and TKI rivoceranib had clinical data presented in the Phase III CARES-310 trial, which enrolled 543 patients. Like Focus V and penpulimab, this IO-TKI combination was compared against sorafenib in first-line HCC. The trial demonstrated similar results to APOLLO, with the IO-TKI arm generating significant benefits to PFS (5.6 vs 3.7 months, p<0.0001) and OS (22.1 vs 15.2 months, p<0.0001). One area where Focus V and penpulimab seem to hold an edge is in their safety profile. There were fewer TRAEs when compared to sorafenib. This wasn’t seen with the camrelizumab and rivoceranib combination. Focus V and penpulimab are competitive IO-TKIs in the first-line landscape for treating aHCC and generally exhibit a well-tolerated safety profile.
Ultimately, the greatest competition lies outside of the IO-TKI domain. The field has seen Roche’s Tecentriq (atezolizumab) with bevacizumab rise as a first-line standard-of-care in the aHCC space. This approval was granted on the back of a Phase III trial that showed Tecentriq and bevacizumab combination significantly improved median PFS compared to sorafenib alone (6.8 vs. 4.3 months, p<0.001) and had a relatively indifferent safety profile.
GlobalData’s patient-based HCC forecast predicts Tecentriq sales will grow to $980m across the eight major markets (US, UK, Spain, Germany, Italy, France, China, and Japan) by 2029. While the Focus V and penpulimab combination is offering strong performance, it is not the first in the IO-TKI space to demonstrate tangible results and they will face great difficulty toppling Tecentriq from its current seat atop the aHCC first-line treatment paradigm.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
CMP Corporation
MyData
CDM NV
Cassie